SCHEMBL2686341

SCHEMBL2686341

[CH](Nc1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.52
NOX1 Q9Y5S8 1/20 0.44
TDP1 Q9NUW8 3/20 0.43
HSD17B10 Q99714 2/20 0.43
CTSD P07339 1/20 0.43
TSHR P16473 3/20 0.41
PTGS2 P35354 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPK1 P28482 2/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
PTGS1 P23219 1/20 0.41
SLC6A2 P23975 1/20 0.41
HTR2B P41595 1/20 0.41
LMNA P02545 3/20 0.39
IDO1 P14902 2/20 0.39
MAOB P27338 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27599507 0.84 CYP19A1 (0.44) ALDH1A1TDP1NPC1RAB9ASMN1; SMN2
SCHEMBL12479193 0.79 CYP11B2 (0.57) ALDH1A1MAPK1NPC1RAB9ANPSR1
SCHEMBL10728528 0.75 ALDH1A1 (0.53) ALDH1A1HSD17B10L3MBTL1MAPK1ALOX12
SCHEMBL11331899 0.74
SCHEMBL291980 0.74 ALDH1A1 (0.48) ALDH1A1NOX1MAPK1LMNAIDO1
SCHEMBL223592 0.73 ALDH1A1 (0.60) ALDH1A1TDP1HSD17B10CTSDTSHR
SCHEMBL446252 0.73 ALDH1A1 (0.45) ALDH1A1NOX1TSHRL3MBTL1MAPK1
SCHEMBL223591 0.73 ALDH1A1 (0.60) ALDH1A1TDP1HSD17B10CTSDTSHR
SCHEMBL7492108 0.73 ALDH1A1 (0.60) ALDH1A1TDP1HSD17B10CTSDTSHR
SCHEMBL5098432 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016123627-A1 ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOUNDS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY (US) 2016-08-04 WO claimed
EP-0132814-B1 ESTER DERIVATIVE OF SUBSTITUTED ACETIC ACID AND PREPARING THE SAME Kaken Pharmaceutical Co., Ltd. (JP) 1988-12-21 EP claimed
US-4603217-A ANTIINFLAMMATORY AGENTS KAKEN PHARMACEUTICAL CO., LTD. (JP) 1986-07-29 US claimed
EP-0132814-A1 Ester derivative of substituted acetic acid and preparing the same Kaken Pharmaceutical Co., Ltd. (JP) 1985-02-13 EP claimed
US-20170158681-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2017-06-08 US disclosed
US-8168634-B2 Thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-05-01 US disclosed
CN-102159535-A Potassium ion channel modulators and uses thereof UNIV RAMOT 2011-08-17 CN disclosed
US-20100298310-A1 Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-11-25 US disclosed
EP-2084155-A1 THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-08-05 EP disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2008047109-A1 THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-04-24 WO disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed
US-4727060-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1988-02-23 US disclosed
US-4719288-A HYPOTENSIVE CIBA-GEIGY CORPORATION (US) 1988-01-12 US disclosed
US-4613676-A PEPTIDES CIBA-GEIGY CORPORATION (US) 1986-09-23 US disclosed
US-4603217-A ANTIINFLAMMATORY AGENTS KAKEN PHARMACEUTICAL CO., LTD. (JP) 1986-07-29 US disclosed
EP-0184550-A2 5-Amino-4-hydroxy valeryl amide derivatives CIBA-GEIGY AG (CH) 1986-06-11 EP disclosed
EP-0143746-A2 5-Amino 4-hydroxy-valeryl-substituted derivatives CIBA-GEIGY AG (CH) 1985-06-05 EP disclosed
EP-0132814-A1 Ester derivative of substituted acetic acid and preparing the same Kaken Pharmaceutical Co., Ltd. (JP) 1985-02-13 EP disclosed
US-3895063-A Substituted Anilino Benzyl Alcohols CIBA GEIGY CORP 1975-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158681-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5A, KDM1A ALDH1A1 588/4885NOX1 992/4885TDP1 179/4885
US-20100298310-A1 Thiazole Derivatives as Kinase Inhibitors TEC, BTK, PI4KA ALDH1A1 3055/4885NOX1 1270/4885TDP1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.